|Leave a Message or Start an on-line Chat
Recombinant full-length human CCR8 protein was expressed by the intact DNA sequence of the human CCR8 in mammalian cells. This recombinant CCR8 protein was fused with a 10xHis-tag at the C-terminus. It contains less than 1.0 EU/ug determined by the LAL method. The CCR8 protein is biologically active as it can react with the mouse anti-6xHis monoclonal antibody and anti-CCR8 recombinant antibody, respectively. Its VLP-like structure was observed and confirmed by TEM. This recombinant CCR8 protein is highly immunogenic because it carries viral protein.
Past studies have shown that the CCR8 protein is mainly expressed on monocytes, Th2 cells, and Treg cells. Many basic studies have also proved CCR8 plays an essential role in the biological processes of lymph node migration of monocyte-derived dendritic cells and Th2 cell-mediated type 2 inflammation. Researchers have found that CCR8 is a good biomarker of Treg cells at tumor sites and a potential tumor immune target. Subsequent studies found that the presence or absence of CCR8 does not affect the migration ability of Treg and its function in the tumor microenvironment. The development of CCR8-targeted monoclonal antibody drugs is expected to specifically inhibit the function of Treg at the tumor site and contribute to cancer treatment.
Applications : Drug related studies
Review: CCR8 is a multi-pass transmembrane protein, and expressing only its extracellular domain can disrupt its conformational epitopes, resulting in the loss of some antigenic epitopes. Your company has developed this full-length protein with good biological activity and immunogenicity. It will be very helpful for our company\'s subsequent development of antibody drugs.
I notice you provide CCR8 nanodiscs, could you inform me about the exposure of both the intracellular and extracellular domain? We would like to screen a panel of antibodies with potency for detecting either intracellular or extracellular epitopes of this target.
For a VLP, per definition the intracellular domain is not exposed, as I am aware of, which is not ideal for our purpose.
VLP only exposes the extracellular domain, and the intracellular domain is not exposed in the envelope, which is mainly to screen and recognizes the extracellular epitopes, so VLP may not be suitable for customers' experiments. The customer would like to screen a group of antibodies that can detect the intracellular or extracellular site of the target. We recommend CSB-CF004847HU ，which express full-length protein by a cell-free expression system, but no activity test was performed and it is not guaranteed to identify the endogenous sample. Or it is suggested that the customer select the intracellular or extracellular domain sequence of the target protein for recombinant expression, and screen the antibodies that identify the intracellular or cellular epitopes of the target, but can not guarantee the recognition of endogenous samples.